Tivic Health Systems
Develops TLR5 immunotherapies and biomanufacturing services for radiation and oncology uses.
Something off on this page? Send us feedback.
Profile
Tivic Health Systems is a Nasdaq-listed healthcare company that shifted from consumer bioelectronic devices to clinical-stage immunotherapy. Its lead candidate is Entolimod, a TLR5 agonist for acute radiation syndrome, and its Velocity Bioworks subsidiary adds biomanufacturing and CDMO services.
Tivic Health Systems, Inc. is a clinical-stage biopharmaceutical company that trades on the Nasdaq Capital Market under TIVC. The company repositioned in 2025 from a consumer bioelectronic medical-device business into an immunotherapy-focused platform built around Toll-like Receptor 5 biology. Its lead program, Entolimod, is being developed for acute radiation syndrome and related radiation or oncology supportive-care uses; filings describe it as pre-BLA under the FDA Animal Rule and note Fast Track and Orphan Drug designations.
Tivic also holds rights to Entolasta, a next-generation TLR5 agonist. Its Velocity Bioworks subsidiary in San Antonio provides internal manufacturing support and offers CDMO services to external biotech customers. The company discontinued ClearUP operations and suspended non-core neuromodulation work, so execution now depends on clinical, regulatory, government funding, manufacturing, and CDMO customer progress.
Company facts
Key statistics
Year to date −81.9% · Average volume (30d) 13.7M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026Q4 FY25 | −$408.00 | −$2.23 | +99.5% | $460.0K | — | — | −1.01% |
| Mar 25, 2026Q4 FY25 | — | −$0.90 | — | — | −$302.0K | — | −13.26% |
| Nov 14, 2025Q3 FY25 | — | −$1.97 | — | — | $146.0K | — | −21.47% |
| Aug 14, 2025Q2 FY25 | — | −$2.19 | — | — | $86.0K | — | +8.29% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $70.0K | $86.0K | $146.0K | −$302.0K | $0 | $0 | |
| Gross profit | $50.0K | $54.0K | −$145.0K | −$302.0K | $0 | −$358.0K | |
| Operating income | −$1.5M | −$1.9M | −$2.5M | −$2.0M | −$5.6M | −$6.4M | |
| Net income | −$1.5M | −$1.9M | −$2.6M | −$2.8M | −$6.2M | −$7.1M | |
| Diluted EPS | −$2.52 | −$2.19 | −$1.97 | −$0.90 | −$2.23 | −$2.10 | |
| Gross margin | 71.4% | 62.8% | -99.3% | — | — | — | |
| Operating margin | -2,151.4% | -2,248.8% | -1,700.7% | — | — | — |
Fiscal years (4-quarter sums)FY21 $1.2M · FY22 $1.8M · FY23 $1.2M · FY24 $780.0K · FY25 $0
Revenue by product · FY24
Balance sheet, Jun 30, 2026Cash & short-term investments $2.1M · Total debt $10.0M · Total assets $32.5M · Shareholders' equity $11.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 1.08M · Float 1.03M
This issuer lists more than one class and the share count spans them all, so a stake here reads as a share of the whole company, not of this class.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % of company | Form | Filed |
|---|---|---|---|---|
| Geode Capital Management, LLC | 87.8K | 8.11% | 13F | May 15, 2026 |
| Sanctuary Advisors, LLC | 61.2K | 5.65% | 13F | May 5, 2026 |
| Marex Group PLC | 59.3K | 5.47% | 13F | May 13, 2026 |
| HRT Financial LP | 42.4K | 3.92% | 13F | May 14, 2026 |
| Jennifer Ernst · director, officer: Chief Executive Officer | 32.7K | 3.02% | Form 4 | Dec 22, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 15, 2026 | Sheryle Bolton | director | +10,000 | $1.04 |
| Apr 1, 2026 | Christina Rizopoulos Valauri | director | +19,000 | $0.9478 |
Peers
Not reported.